Shutterstock.com
The Royal Pharmaceutical Society (RPS) is inviting feedback on its draft pharmacogenomic resource for all prescribers, as part of an open consultation.
In a statement published on 1 December 2025, the RPS said the resource will be aimed at everyone in a prescribing role, aimed to help prescribers apply pharmacogenomics knowledge within their existing prescribing competencies so they can prescribe safely and effectively using pharmacogenomic testing.
According to the statement, the draft resource, commissioned by the NHS England ‘Network of excellence in pharmacogenomics and medicines optimisation’, focuses on two domains: consultations, and prescribing.
Within each domain is a list of competencies taken from the RPS ‘Competency framework for all prescribers’, published in September 2021, with additional reflections on how these competencies apply to pharmacogenomics, it added.
The RPS said that the draft resource also includes case studies to help show the context of pharmacogenomics in prescribing.
It will also be suitable for individuals undertaking self-assessment or portfolio development, organisations developing prescribing practice and governance systems, as well as regulators, educators and professional bodies who are producing standards and developing curricula, the RPS said.
Sophie Harding, lead author of the resource and consultant pharmacist for genomics and pharmacogenomics, said: “Pharmacogenomics has the potential to improve patient outcomes by ensuring that prescribing is better targeted, more personalised and more effective.
“We want to develop a resource that is practical, high-quality and useful for every prescriber, regardless of setting, profession or level of experience.
“Your feedback will help us shape a tool that reflects real-world practice and supports safe, evidence-based clinical decision-making,” she added.
In February 2025, Queen Mary University of London published results of a survey, which suggested that almost 90% of people would agree to pharmacogenomics testing to get the most effective medicine and reduce side effects.
Results from the ongoing ‘PROGRESS’ trial — a research study designed to establish the feasibility of providing an NHS-wide pharmacogenomics service — show that one-quarter of patients taking part had their prescriptions changed after receiving their genetic testing results.
However, concerns have been raised of an ethnicity gap in pharmacogenomics data and the need for genomic testing to reflect the full ethnic diversity of populations.
The consultation, which can be completed here, closes on 9 January 2026.
